Aarti Pharmalabs Limited (AARTIPHARM) — Financial Results | 10 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Q1 FY27 standalone revenue up 42.4% YoY to ₹5,346 crores
🔄 What Changed
Revenue +42.4% YoY; EBITDA +39.5% YoY; PAT +49.2% YoY; EBITDA margin 24.82%
🔮 What's Next
Commercialization of Atali Block 2 capex (₹149 crores) by H2 FY28; FY27 capex expected at ~INR 400 crores; R&D investment in TIDES (Peptides & Oligonucleotides) in FY27
💡 Investor Takeaway
Revenue and profit growth accelerated YoY, driven by capacity expansion and operational improvements, with strategic capex and R&D plans targeting future market share gains.

Aarti Pharmalabs Limited reported standalone revenue of ₹5,346 crores for Q1 FY27, up 42.4% YoY from ₹3,753 crores in Q1 FY26, with EBITDA rising 39.5% YoY to ₹1,327 crores. PAT reached ₹713 crores, a 49.2% YoY increase, and EBITDA margin expanded to 24.82%. The company highlighted capacity expansion in xanthine derivatives, new R&D initiatives, and a ₹149 crore Atali greenfield capex project targeting commercialization by H2 FY28. Forward-looking statements were included in the presentation disclaimer.

📄 View Original Announcement (PDF)

About Aarti Pharmalabs Limited (AARTIPHARM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹7,657.91 Cr P/E: 35.9 ROE: 10.7% ROCE: 14.1% Div Yield: 0.41%

View full AARTIPHARM stock details →

📡 Get AI alerts when AARTIPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AARTIPHARM — Free

📊 More AARTIPHARM filings

See all AARTIPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AARTIPHARM files new disclosures

Track AARTIPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AARTIPHARM — Free

Free account · 2 AI queries/day